



香港聯合交易所有限公司
(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

ANNOUNCEMENT

In relation to the trading suspension of
Boill Healthcare Holdings Limited (the **Company**)
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1246)

This announcement is made by The Stock Exchange of Hong Kong Limited (the **Exchange**) pursuant to Rule 2.07(2)(e) of the Rules Governing the Listing of Securities on the Exchange and Section 21 of the Securities and Futures Ordinance.

Company Announcements

On 22 July 2024, the Company issued an announcement (**Announcement A**) regarding the resignation of three directors and the appointment of four new directors with effect from 22 July 2024.

At approximately 6:59 a.m. on 24 July 2024, the Company issued a clarification announcement clarifying that there had been no change to the composition of the board since 8 March 2024, and Announcement A was released by the then company secretary of the Company without proper authorisation of the Company's board.

At approximately 10:30 p.m. on 24 July 2024, the Company issued a further clarification announcement clarifying, among others, that the changes of directors disclosed in Announcement A had been reviewed and approved by the Company's board at the time, and the board had further approved the re-designation of chairman of the board from Mr. Qiu Dongfang to Mr. He Yu, an executive director newly appointed on 22 July 2024, with effect from 24 July 2024.

Trading Suspension and Resumption Guidance

At 9:31 a.m. on 25 July 2024, trading of the securities of the Company was suspended at the request of the Company pending release of an announcement in relation to inside information.

On 26 July 2024, the Exchange informed the Company of the following resumption guidance for the resumption of trading in the Company's securities:

- (i) demonstrate, with appropriate evidence and to the Exchange's satisfaction, the correct identities of the individuals who make up the board of directors of the Company and their respective roles and functions; and
- (ii) inform the market of all material information for the Company's shareholders and investors to appraise the Company's position.

The Company's access to the Exchange's e-Submission system is suspended pending its clarification of board composition and authorised representatives of the e-Submission account.

Hong Kong, 9 August 2024